Mallika Dhawan, MD

Oncologist

Dr. Mallika Dhawan is a medical oncologist who specializes in treating patients with hereditary cancers as well as those with genitourinary malignancies. She also sees patients in the Developmental Therapeutics clinic, which focuses on finding novel treatments for cancer patients.

In addition to patient care, Dhawan designs clinical trials in the Developmental Therapeutics clinic for patients with prostate cancer. She also studies cancer prevention in patients with hereditary cancer mutations.

Dhawan earned her bachelor's degree in engineering and her medical degree at the University of California, San Diego. She completed a residency in internal medicine at Duke University before returning home to the San Francisco Bay Area for an oncology fellowship at UCSF. While completing her fellowship, she won a grant from UCSF's Precision Health Science TL1 Postdoctoral Fellowship Training Program.

Dhawan is a clinical instructor at UCSF and continues to advance her training in precision medicine. Outside of work, she enjoys spending time with her husband and family.

Clinics

Hereditary Cancer Clinic
1600 Divisadero St., H Building, Fourth Floor
San Francisco, CA 94115
Phone: (415) 353-9797
Fax: (415) 353-8216

Hours: Monday to Friday, 8 a.m. – 5 p.m.

Conditions & Treatments

  • Hereditary Cancer Syndromes

Academic Title

Assistant Professor

More about Mallika Dhawan

Education

UC San Diego, B.S., Engineering 2006
UC San Diego School of Medicine 2011

Residencies

Duke University Medical Center, Internal Medicine 2011

Fellowships

UCSF, Oncology 2017

Selected Research and Publications

  1. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107.
  2. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410.
  3. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Apr; 35(4):149.e7-149.e13.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.